US Broker Ratings

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Unraveling a 42.71% Potential Upside in Precision Medicine

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has captured the attention of investors with its focus on precision medicine within the biotechnology sector. Headquartered in South San Francisco, California, this innovative company..

PACS Group, Inc. (PACS) Investor Outlook: A Promising 36% Upside in the Healthcare Sector

PACS Group, Inc. (NASDAQ: PACS) has emerged as a noteworthy player in the healthcare sector, specifically within the medical care facilities industry. Focused on providing skilled nursing and assisted living..

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Exploring a Promising 41% Upside Potential

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stands out in the biotechnology sector, with a focus on innovative solutions for neurological and rare diseases. With a market capitalization of $3.85 billion, the..

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Biotech Growth with a 39.77% Upside Potential

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) presents a compelling opportunity for investors with its strong growth trajectory in the biotechnology sector, a promising pipeline of drug candidates, and a potential upside..

Organon & Co. (OGN) Stock Analysis: Navigating the 37.83% Potential Upside Amidst Market Challenges

Organon & Co. (NYSE: OGN), a healthcare company specializing in women’s health solutions and biosimilars, presents an intriguing opportunity for investors willing to navigate its current market challenges. With a..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Exploring a 26.69% Potential Upside in the Biotech Sector

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is carving out a niche in the biotechnology sector with its innovative approach to eye care and disease prevention. Investors are taking note, as the..

HUTCHMED (China) Limited (HCM) Stock Analysis: Navigating the 55.60% Potential Upside Amidst Revenue Challenges

HUTCHMED (China) Limited (HCM) is attracting significant attention from investors as it boasts a promising potential upside of 55.60% according to analysts’ average target price. Despite a challenging revenue environment,..

Beam Therapeutics Inc. (BEAM): Investor Outlook on a Biotech with 80% Upside Potential

Beam Therapeutics Inc. (NASDAQ: BEAM) stands out in the biotechnology sector with its robust pipeline of precision genetic medicines, targeting serious diseases through innovative therapies. Founded in 2017 and based..

Viking Therapeutics, Inc. (VKTX) Stock Analysis: Unpacking the 175% Potential Upside

Investors are taking a keen interest in Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, as it continues to make waves in the biotechnology sector. With a market capitalization..

Privia Health Group, Inc. (PRVA): Analyst Consensus Highlights 36.7% Upside Potential

For investors keen on tapping into the healthcare sector’s burgeoning technology and services segment, Privia Health Group, Inc. (NASDAQ: PRVA) presents a compelling opportunity. The company’s focus on physician enablement..

CG Oncology, Inc. (CGON) Stock Analysis: Unpacking a 31% Potential Upside in Biotech’s Hot Sector

As CG Oncology, Inc. (CGON) continues to make waves in the healthcare sector, particularly within the biotechnology industry, investors are taking a keen interest in its promising pipeline and substantial..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Evaluating a 28% Upside Potential in Biotech

PTC Therapeutics, Inc. (NASDAQ: PTCT) is making waves in the biotechnology sector, offering investors an intriguing opportunity given its current market positioning and growth prospects. With a market cap of..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Exploring a 12.76% Potential Upside in the Healthcare Sector

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the healthcare sector with a market capitalization of $2.56 billion, operates at the intersection of medical instruments and supplies. This Charlotte-based..

Veracyte, Inc. (VCYT): Investor Outlook Highlights 42% Potential Upside

Veracyte, Inc. (NASDAQ: VCYT), a prominent player in the healthcare sector specializing in diagnostics and research, is currently capturing the attention of investors thanks to a promising potential upside of..

Progyny, Inc. (PGNY) Investor Outlook: Exploring a 56.91% Potential Upside in Healthcare Plans

Progyny, Inc. (NASDAQ: PGNY) stands out in the healthcare sector as a prominent player in the niche market of fertility and family-building benefits. For investors seeking a company with significant..

Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 68.77% Upside Potential in Biotechnology

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stands at the forefront of the biotechnology sector, with a market capitalization of $2.56 billion. Headquartered in Waltham, Massachusetts, this commercial-stage biopharmaceutical company is making..

UFP Technologies, Inc. (UFPT) Stock Analysis: Exploring a 50.93% Upside Potential in the Medical Device Sector

UFP Technologies, Inc. (UFPT), a key player in the medical device sector, is drawing significant attention from investors due to its robust market positioning and impressive growth potential. Headquartered in..

Sotera Health Company (SHC) Stock Analysis: A 42% Potential Upside Beckons Investors

Sotera Health Company (NASDAQ: SHC) stands as a notable player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $4.14 billion, the company..

Ardent Health, Inc. (ARDT) Stock Analysis: Navigating a 39.77% Potential Upside in the Healthcare Sector

Ardent Health, Inc. (ARDT) is garnering attention within the healthcare sector for its potential upside of nearly 40%, according to recent analyst ratings. Operating in the medical care facilities industry,..

Alvotech (ALVO) Stock Analysis: Is a 368% Upside Within Reach for This Biosimilar Pioneer?

Alvotech (NASDAQ: ALVO) is steadily carving out its niche in the healthcare sector, focusing on the development and manufacturing of biosimilar medicines. With a market capitalization of $1.25 billion, Alvotech..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds